MYLAN-TRAMADOL/ACET TABLET Canada - English - Health Canada

mylan-tramadol/acet tablet

mylan pharmaceuticals ulc - tramadol hydrochloride; acetaminophen - tablet - 37.5mg; 325mg - tramadol hydrochloride 37.5mg; acetaminophen 325mg - opiate agonists

Clopidogrel DURA European Union - English - EMA (European Medicines Agency)

clopidogrel dura

mylan dura gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Docetaxel Mylan European Union - English - EMA (European Medicines Agency)

docetaxel mylan

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.

Ritonavir Mylan European Union - English - EMA (European Medicines Agency)

ritonavir mylan

mylan s.a.s - ritonavir - hiv infections - antivirals for systemic use - ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv 1 infected patients (adults and children of 2 years of age and older).

Tigecycline Mylan 50 mg powder for solution for infusion Malta - English - Medicines Authority

tigecycline mylan 50 mg powder for solution for infusion

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - tigecycline - powder for solution for infusion - tigecycline 50 mg - antibacterials for systemic use

Rasagiline Mylan European Union - English - EMA (European Medicines Agency)

rasagiline mylan

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Sugammadex Mylan European Union - English - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sitagliptin / Metformin hydrochloride Mylan European Union - English - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist.sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.